Tecelra Injection, Suspension
NDC 87262-160

View dosage, usage, ingredients, routes, and UNII mappings.
Table of Contents
  1. Product Information
  2. Product Packages
  3. What is NDC 87262-160?
  4. Tecelra Uses
  5. Active Ingredients
  6. Active Ingredients UNII Codes
  7. Inactive Ingredients UNII Codes
  8. NDC to RxNorm Crosswalk
  9. Patient Education

Product Information

Tecelra (afamitresgene autoleucel) is a BLA-approved product labeled by Uswm Ct, Llc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a injection, suspension for intravenous administration. This product entry covers the primary NDC 87262-160 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.

Primary Identification

NDC Product Code:
87262-160
Proprietary Name:
Tecelra
Non-Proprietary Name: [1]
Afamitresgene Autoleucel
Substance Name: [2]
Afamitresgene Autoleucel
NDC Directory Status:
Cellular Therapy
Product Type: [3]
ACTIVE PRODUCT INCLUDED in the NDC Directory
Code Navigator:

Clinical Specifications

Dosage Form:
Injection, Suspension - A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa.
Administration Route(s): [4]
Intravenous - Administration within or into a vein or veins.

Labeler & Regulatory Data

Labeler Name: [5]
Uswm Ct, Llc
Labeler Code:
87262
Product Label ID:
2ddd66e1-8036-4a4e-babe-4d673e660bf5
FDA Application Number: [6]
BLA125789
Marketing Category: [8]
BLA - A product marketed under an approved Biologic License Application.

Marketing Timeline

Start Marketing Date: [9]
01-19-2026
Listing Expiration Date: [11]
12-31-2027
Exclude Flag: [12]
N

Code Structure Chart

Product Details

What is NDC 87262-160?

The NDC code 87262-160 is assigned by the FDA to the product Tecelra. It is commonly known by its generic name, afamitresgene autoleucel. This pharmaceutical product is labeled by Uswm Ct, Llc and is currently categorized as listed product. The medication is a injection, suspension administered via intravenous route. In terms of distribution, this product is available in a single package configuration. The associated package NDC(s) include: 87262-160-02. Beyond standard identification, this entry provides technical data including pharmacologic classes, UNII ingredient references, and RxNorm cross-referencing for healthcare systems.

What are the uses of this product?

TECELRA is a melanoma-associated antigen A4-(MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.This indication is approved under accelerated approval based on overall response rate and durability of response [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

What are Active Ingredients of this product?

An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.

Which are the associated UNII Codes?

The UNII codes for the active ingredients in this product are:

  • AFAMITRESGENE AUTOLEUCEL (UNII: CUY18BJ7BP)
  • AFAMITRESGENE AUTOLEUCEL (UNII: CUY18BJ7BP) (Active Moiety)

Which are the Inactive Ingredients associated UNII Codes?

The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:

What is the NDC to RxNorm Crosswalk for this product?

RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
  • RxCUI: 2690269 - afamitresgene autoleucel 10,000,000,000 CELLS in 250 ML Injection
  • RxCUI: 2690269 - 250 ML afamitresgene autoleucel 40000000 CELLS/ML Injection
  • RxCUI: 2690269 - afamitresgene autoleucel 10,000,000,000 CELLS per 250 ML Injection
  • RxCUI: 2690275 - Tecelra 10,000,000,000 CELLS in 250 ML Injection
  • RxCUI: 2690275 - 250 ML afamitresgene autoleucel 40000000 CELLS/ML Injection [Tecelra]

* Please review the full disclaimer at the bottom of this page.

Patient Education

Afamitresgene Autoleucel Injection


Afamitresgene autoleucel is used in adults to treat certain types of synovial sarcoma that cannot be treated with surgery or is unresponsive to other treatments. Afamitresgene autoleucel is in a class of medications called autologous cellular immunotherapy, a type of medication prepared using cells from the patient's own blood. It works by causing the body's immune system (a group of cells, tissues, and organs that protects the body from attack by bacteria, viruses, cancer cells, and other substances that cause disease) to fight the cancer cells.
[Learn More]


Cancer Immunotherapy


What is immunotherapy?

Immunotherapy is a cancer treatment that helps your immune system fight cancer. It is a type of biological therapy. Biological therapy uses substances made from living organisms or versions of these substances made in a lab. Immunotherapy isn't used for all cancers, and the response to treatment varies. If you're getting immunotherapy, your health care provider will monitor your treatment closely.

When is immunotherapy used for cancer treatment?

Immunotherapy isn't used as often as other cancer treatments, such as surgery, chemotherapy, and radiation therapy. But immunotherapy is used for some types of cancer, and researchers are doing clinical trials to see whether it also works for other types.

How does immunotherapy work against cancer?

Cancer begins in your cells, which are the building blocks of your body. Usually, your body forms new cells as needed, replacing old cells that die. Sometimes, this process goes wrong. When you have cancer, some of your cells begin to multiply without stopping, and old cells don't die when they should. They spread into the surrounding tissues.

One reason cancer cells can keep growing and spreading is that they can hide from your immune system. Some immunotherapies can "mark" your cancer cells. This makes it easier for your immune system to find and destroy the cells. It is a type of targeted therapy that uses medicines or other substances that attack specific cancer cells with less harm to normal cells. Other types of immunotherapies work by boosting your immune system to work better against cancer.

How is immunotherapy given?

There are different forms of immunotherapy, so how they are given varies. You could get immunotherapy intravenously (by IV), in pills or capsules, or cream for your skin. For bladder cancer, they might place it directly into your bladder.

How often and how long you get immunotherapy also varies. It depends on your type of cancer, how advanced it is, the type of immunotherapy you get, and how well it is working. You may have treatment every day, week, or month. Some immunotherapies are given in cycles, so your body has time to rest and recover.

What are the side effects of immunotherapy?

You may have side effects. The most common side effects are skin reactions at the needle site if you get it by IV. Other side effects may include flu-like symptoms or, rarely, severe reactions.

NIH: National Cancer Institute


[Learn More]


* Please review the full disclaimer at the bottom of this page.

Product & Regulatory Definitions
What is the Non-Proprietary Name? The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
What is the Substance Name? An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
What kind of product is this? Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
What are the Administration Routes? The translation of the route code submitted by the firm, indicating route of administration.
What is the Labeler Name? Name of Company corresponding to the labeler code segment of the Product NDC.
What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".